Cell Counting Market – A Complete Analysis
Cell counting is the technique of counting cells in pharmaceutical, biotechnology, and other clinical & medical research operations for a variety of medicinal purposes. Cell counts are used to calculate the number of cells per volume in liquid media. The cell counting method required to determine additional operations requires multiple treatments. When conducting research and experimentation, cell counting makes it easier to maintain cell cultures and aids in the preparation of cells for transfection and subsequent studies.
The market for cell counting in 2021 was USD 10.48 billion and will be worth USD 19.27 billion by 2030 at a 7% CAGR during 2021-2030.
Cell counting techniques are becoming increasingly popular as the incidence of numerous chronic diseases, such as cancer, HIV-AIDS, leukemia, Alzheimer’s disease, etc., rises. The development of next-generation medicines is also accelerating the market expansion as more medical specialties, including molecular biology, immunology, pathology, etc., are adopting cell counting tools.
- The rising prevalence of target diseases like HIV, measles, diphtheria, chronic conditions like cancer, hemophilia, and other blood disorders, is what fuels the worldwide cell counting industry. By the end of 2020, the World Health Organization predicts that close to 37.7 million people will be living with HIV worldwide. In addition, 680,000 people passed away in 2020 from HIV-related causes, and 1.5 million more are at risk of contracting the disease in the years to come. Therefore, rising infectious disease instances will fuel the industry’s rapid expansion.
- Additionally, technological advancements in cell counting tools or reagents have increased product launches, fueling the market’s expansion. For instance, the DeNovix Inc. product The CellDrop, an automated cell counter that enables researchers to count cells without using slides, won the Best New Life Science Product of the Year Award on May 19, 2020.
The high cost of complex cell counting technologies, a lack of skilled workers, and product recalls involving haematology analyzers restrain the growth of the global cell counting industry.
The rising rate of chronic blood disorders will drive the growth of the global market for cell counting. As per a study in 2020, the incidence rate of leukaemia worldwide is 274,519 with 311, 549 death due to the disease. Because of these disorders high fatality and prevalence, the rate of adoption will increase, resulting in market growth in the future.
In 2021, consumables and accessories contributed for more than 50.0% of total revenue. Reagents, microplates, magnetic beads, and chamber slides are some of the consumables and accessories utilized with these gadgets. Their high usage volume is a contributing factor in the expansion of consumables and accessories. Additionally, the introduction of innovative items spurs market expansion.
In 2021, complete blood count had the highest revenue share of 55.0%. The complete blood count is frequent test to assess a person’s general health. The test measures several blood components, including RBC, WBC, hemoglobin, hematocrit, and platelets. The growing prevalence of blood illnesses, including leukemia and anemia, which complete blood counts frequently monitor, will fuel segment growth.
Academic and research institutions led the entire market with the largest share of 35.0% in 2021. The widespread use of cytometers in cell biology research investigations can be blamed for the large share. Researchers use cytometers to measure criteria like physical characteristics, kind, and lineage to track the evolution of viruses, diseases, and other bacteria. The segment is further driven by strategic actions taken by major market participants.
Due to the growing emphasis on biomedical and cancer research, North America held the greatest revenue share of about 35.0% in 2021. One of the key factors influencing the use of these devices is the rise in the prevalence of chronic diseases, such as blood and cardiovascular disorders. According to the American National Red Cross, 90,000 to 100,000 Americans are affected by sickle cell disease.
Asia Pacific regional market will increase exponentially. This region’s clinical research and biopharmaceutical business concentration can be blamed for the exponential CAGR. In addition, the region’s market is primarily driven by the aging geriatric population, which is extremely sensitive to chronic ailments.
- PerkinElmer Inc
- Olympus Corporation
- Thermo Fisher Scientific Inc
- Merck KGaA
- HORIBA Ltd
- Tecan Trading AG
- Logos BiosystemsInc
- Corning Incorporated
- General Electric Company
- Tip Biosystems
- Agilent Technologies Inc
- Sysmex Corporation
- Boule Diagnostics AB
- Becton, Dickinson, and Company
- Siemens Healthcare Private Limited
- ChemoMetec A/S
- Bio-Rad Laboratories Inc
- R&D Systems, Inc.
- Beckman Coulter Inc
- Nexcelom Bioscience LLC
- Advanced Instruments
- Cole-Parmer Instrument Company LLC
The market for cell counting in 2021 was USD 10.48 billion and will be worth USD 19.27 billion by 2030 at a 7% CAGR during 2021-2030. Market expansion is due to the rising demand for biologics to treat chronic diseases. The use of various cell counting tools during biologics development, including flow cytometers and spectrophotometers, helps manage cell concentration in biologics and boosts the market’s growth prospects.